小分子汎KRAS分解剤でがんを標的とする

Johannes Popow¹, William Farnaby^2,3, Andreas Gollner¹

¹Boehringer Ingelheim RCV GmbH & Co KG, 1221 Vienna, Austria.

Science (New York, N.Y.)

|September 19, 2024

まとめ

研究者は,最も一般的ながんを誘発するキルステン・ラット・サーコマウイルス性腫瘍遺伝子ホモログ (KRAS) 変異を退廃させる新しい小分子を開発し,KRAS誘発がんに対する新しい治療戦略を提供した.

科学分野:

腫瘍学
分子生物学
薬物の発見

背景:

キルステン・ラット・サーコマのウイルス性腫瘍遺伝子の同型 (KRAS) の変異は,がんの一般的な誘発因子である.
KRAS G12Cのような特定の変異に限定された現在の治療法により,腫瘍性KRASを標的とするのは困難である.

研究の目的:

主要な腫瘍性KRASアレルの分解のための新しいヘテロバイ機能小分子を設計し,評価する.
KRASの分解と抑制の有効性をがんモデルで比較する.

主な方法:

KRAS三重複合体の生体物理学的および構造的研究
ヘテロバイ機能小分子の設計と合成
KRAS変異がん細胞系における KRAS分解の評価
経路の調節と抗がん活性 in vitro と in vivo の評価

主要な成果:

設計された小分子は17の有病性KRASアレルのうち13を強力に分解した.
KRASの分解は,抑制と比較して,より深刻で持続的な経路調節につながった.
降解は選択的にKRAS異常を有する癌細胞を殺し,体内で許容され,腫瘍の逆行を引き起こした.

結論:

小分子媒介による腫瘍性KRASの分解は,有望な新しい治療法です.
この戦略は,KRAS G12Cを超えて様々なKRAS変異に広く適用できます.
この発見は KRASによる癌の治療に新たな道を開きます

さらに関連する動画

09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.5K

関連する概念動画

02:57

Targeted Cancer Therapies

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.5K

02:50

Combination Therapies and Personalized Medicine

4.9K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

4.9K

02:34

Inhibition of Cdk Activity

4.7K

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

4.7K

02:15

M-Cdk Drives Transition Into Mitosis

5.5K

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

5.5K

02:38

Mitogens and the Cell Cycle

6.4K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

6.4K

03:03

mTOR Signaling and Cancer Progression

3.8K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...